Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1992-12-2
|
pubmed:abstractText |
The hemodynamic profile of pirsidomine, a new donor of NO (nitric oxide), was evaluated in dogs. In anesthetized dogs, the intravenous or intraduodenal administration of pirsidomine (0.3-10 mg/kg) decreased dose relatedly the preload and afterload of the heart, total peripheral resistance, cardiac output, left ventricular work and myocardial oxygen consumption. In conscious renal-hypertensive dogs, oral administration of pirsidomine (1.0-10 mg/kg) caused a marked and sustained decrease in systolic blood pressure and left ventricular end-diastolic pressure, which was accompanied by a slight and transient increase in heart rate and contractility. The diastolic blood pressure was affected less than in anesthetized dogs. Similar hemodynamic effects were obtained with M1 (3-(1-(2,6-dimethylpiperidino))-sydnonimine; 0.3-1 mg/kg), the main metabolite of pirsidomine, and with the known NO donor, isosorbide-5-mononitrate (IS-5-MN; 2-10 mg/kg). Tolerance development after repeated administration of pirsidomine and IS-5-MN was also investigated. In anesthetized dogs, repeated intraduodenal administrations of pirsidomine did not attenuate the response whereas tolerance occurred with hemodynamically equieffective doses of IS-5-MN. In conscious dogs, long term oral treatment, three times daily every 8th h for 5 days, revealed tolerance to IS-5-MN, slight or no tolerance to pirsidomine, and no cross-tolerance between the two agents. The results indicate that pirsidomine possesses an antianginal hemodynamic profile similar to that of its main metabolite, M1, and of IS-5-MN. This suggests a common mode of action via the release of NO.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Isosorbide Dinitrate,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide,
http://linkedlifedata.com/resource/pubmed/chemical/Sydnones,
http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/isosorbide-5-mononitrate,
http://linkedlifedata.com/resource/pubmed/chemical/pirsidomine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0014-2999
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
220
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
71-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1425982-Administration, Oral,
pubmed-meshheading:1425982-Animals,
pubmed-meshheading:1425982-Dogs,
pubmed-meshheading:1425982-Drug Tolerance,
pubmed-meshheading:1425982-Female,
pubmed-meshheading:1425982-Hemodynamics,
pubmed-meshheading:1425982-Hypertension, Renal,
pubmed-meshheading:1425982-Injections, Intravenous,
pubmed-meshheading:1425982-Isosorbide Dinitrate,
pubmed-meshheading:1425982-Male,
pubmed-meshheading:1425982-Nitric Oxide,
pubmed-meshheading:1425982-Sydnones,
pubmed-meshheading:1425982-Vasodilator Agents
|
pubmed:year |
1992
|
pubmed:articleTitle |
Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs.
|
pubmed:affiliation |
Department of Pharmacology, Cassella AG, Frankfurt/Main, Germany.
|
pubmed:publicationType |
Journal Article
|